NASDAQ · SYRS
Healthcare · Biotechnology
$0.01
Up+$0.01 (+2900.00%)
Updated Sep 17, 2026, 4:08 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SYRS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SYRS.
SYRS research
Company profile and research snapshot.
SYROS PHARMACEUTICALS INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 13, 2024 | TD Cowen | Hold | — |
| Nov 13, 2024 | JMP Securities | Market Perform | — |
| Nov 13, 2024 | Brookline Capital | Hold | — |
| Nov 13, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 1, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Investing.com · Jul 3, 2024
Syros Pharmaceuticals director Richard A. Young sold $178,365 worth of company stock, representing 34,837 shares at $5.12 per share. The sale was conducted under a pre-arranged trading plan. Following the sale, Young still owns 8,000 shares of Syros Pharmaceuticals stock.
Zacks Investment Research · May 8, 2024
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -12.50% and 4.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 1, 2024
Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research · May 1, 2024
Alkermes (ALKS) delivered earnings and revenue surprises of -25.42% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SYRS.
No results
No recent SID articles mention SYRS.
